Log in
Enquire now
Alaunos Therapeutics

Alaunos Therapeutics

Alaunos Therapeutics is a company that develops clinical stage cellular immuno-oncology solutions.

OverviewStructured DataIssuesContributors

Contents

alaunos.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Cell therapy
Cell therapy
Stem cell
Stem cell
Healthcare
Healthcare
Immunotherapy
Immunotherapy
Biotechnology
Biotechnology
Biology
Biology
Technology
Technology
Regenerative medicine
Regenerative medicine
...
Location
Houston
Houston
0
CEO
Kevin S. Boyle
Kevin S. Boyle
Legal Name
Alaunos Therapeutics, Inc.0
Number of Employees (Ranges)
11 – 50
Email Address
alex.lobo@sternir.com0
info@alaunos.com0
Phone Number
+12126988802
Full Address
8030 El Rio St Houston, TX 770540
CIK Number
1,107,4210
Place of Incorporation
Delaware
Delaware
0
IRS Number
841,475,6420
Total Funding Amount (USD)
18,833,000
Latest Funding Round Date
November 2, 2010
Stock Symbol
TCRT0
Exchange
Nasdaq
Nasdaq
0
Board of Directors
‌
Chris Bowden
0
Mary Thistle
Mary Thistle
0
‌
Holger Weis
0
‌
Robert Postma
0
‌
Jaime Vieser
0
‌
James Huang
0
Kevin S. Boyle
Kevin S. Boyle
0
Latest Funding Type
Series A
Series A

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
733,000
Previous Name
EasyWeb, Inc.0
Ziopharm Oncology, Inc.0
NetEscapes, Inc.0
SIC Code
2,8340
Ticker Symbol
TCRT0
Overview

Alaunos Therapeutics, formerly known as NetEscapes, EasyWeb, and Ziopharm, is a Texas-based company specializing in developing solutions for the treatment of solid tumors through adoptive T cell receptor engineering (TCR-T) cell therapy. The company was founded in 1998 and initially offered services related to Internet solutions. It is located in Houston, Texas and has partnerships with other healthcare-related organizations, such as The University of Texas MD Anderson Cancer Center and the National Cancer Institute, to work on projects developing biotechnology platforms.

Product

The company has developed solutions that engineer cell therapies to target Neoantigens (neoAg) arising from genomic mutations. Its solutions are designed to deliver tumor-specific killer T cells to large cancer patient populations that do not have many options for their treatments and therapies.

Alaunos Therapeutics has developed two platforms: Sleeping Beauty and hunTR. Sleeping Beauty is a non-viral, transposon/transposase system used to introduce the TCR gene into autologous T cells from the patient. The hunTR platform stands for human neoantigen T-cell receptor, and it utilizes the company's TCR discovery process with a high-throughput TCR functional validation to streamline the addition of high-quality TCRs to the company's existing TCR-T cell therapy infrastructure.

How the hunTR platform works

How the hunTR platform works

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Alaunos Therapeutics Expecting $15.7M in Common Stock Offering

https://www.precisiononcologynews.com/business-news/alaunos-therapeutics-expecting-157m-common-stock-offering#.Y5-K0XbMI2w

Web

November 29, 2022

Alaunos Therapeutics Still Waiting For Home Run (NASDAQ:TCRT)

https://seekingalpha.com/article/4559596-alaunos-therapeutics-still-waiting

Web

November 21, 2022

Why Alaunos Therapeutics Topped the Market on Tuesday

https://markets.businessinsider.com/news/stocks/why-alaunos-therapeutics-topped-the-market-on-tuesday-11689607

Web

September 6, 2022

References

Find more companies like Alaunos Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.